Alvotech (IC:ALVO) — Market Cap & Net Worth
Market Cap & Net Worth: Alvotech (ALVO)
Alvotech (IC:ALVO) has a market capitalization of $1.07 Billion (Ikr131.18 Billion) as of June 16, 2026. Listed on the IC stock exchange, this Iceland-based company holds position #8800 globally and #6 in its home market, demonstrating a 5.25% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alvotech's stock price Ikr421.00 by its total outstanding shares 311601154 (311.60 Million). Review ALVO total debt and obligations to assess the company's total debt and financial obligations.
Alvotech Market Cap History: 2022 to 2026
Alvotech's market capitalization history from 2022 to 2026. Data shows change from $3.76 Billion to $1.07 Billion (-25.40% CAGR).
Alvotech Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alvotech's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
9.21x
Alvotech's market cap is 9.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $3.76 Billion | $83.03 Million | -$513.58 Million | 45.28x | N/A |
| 2023 | $4.03 Billion | $91.43 Million | -$551.73 Million | 44.04x | N/A |
| 2024 | $4.51 Billion | $489.68 Million | -$231.86 Million | 9.21x | N/A |
Competitor Companies of ALVO by Market Capitalization
Companies near Alvotech in the global market cap rankings as of June 16, 2026.
Key companies related to Alvotech by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #512 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #560 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #613 globally with a market cap of $44.69 Billion USD ( CN¥305.43 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #629 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #512 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #560 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.41 |
| #613 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.69 Billion | CN¥47.88 |
| #629 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Alvotech Historical Marketcap From 2022 to 2026
Between 2022 and today, Alvotech's market cap moved from $3.76 Billion to $ 1.07 Billion, with a yearly change of -25.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Ikr1.07 Billion | -33.39% |
| 2025 | Ikr1.61 Billion | -64.39% |
| 2024 | Ikr4.51 Billion | +11.99% |
| 2023 | Ikr4.03 Billion | +7.09% |
| 2022 | Ikr3.76 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Alvotech was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.07 Billion USD |
| MoneyControl | $1.07 Billion USD |
| MarketWatch | $1.07 Billion USD |
| marketcap.company | $1.07 Billion USD |
| Reuters | $1.07 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic art… Read more